VVZ 368

Drug Profile

VVZ 368

Alternative Names: VVZ-368

Latest Information Update: 19 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vivozon
  • Class Analgesics
  • Mechanism of Action Glycine plasma membrane transport protein inhibitors; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Pain

Most Recent Events

  • 28 Apr 2017 Early research in Pain in USA (PO) (Vivozon pipeline, April 2017)
  • 28 Apr 2017 Vivozon has patent protection for benzamide derivatives for the treatment of pain in Korea, USA and China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top